247 related articles for article (PubMed ID: 18230615)
1. A potent HIV protease inhibitor, darunavir, does not inhibit ZMPSTE24 or lead to an accumulation of farnesyl-prelamin A in cells.
Coffinier C; Hudon SE; Lee R; Farber EA; Nobumori C; Miner JH; Andres DA; Spielmann HP; Hrycyna CA; Fong LG; Young SG
J Biol Chem; 2008 Apr; 283(15):9797-804. PubMed ID: 18230615
[TBL] [Abstract][Full Text] [Related]
2. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C; Hudon SE; Farber EA; Chang SY; Hrycyna CA; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13432-7. PubMed ID: 17652517
[TBL] [Abstract][Full Text] [Related]
3. HIV-protease inhibitors block the enzymatic activity of purified Ste24p.
Hudon SE; Coffinier C; Michaelis S; Fong LG; Young SG; Hrycyna CA
Biochem Biophys Res Commun; 2008 Sep; 374(2):365-8. PubMed ID: 18639527
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors inhibit FACE1/ZMPSTE24: a mechanism for acquired lipodystrophy in patients on highly active antiretroviral therapy?
Goulbourne CN; Vaux DJ
Biochem Soc Trans; 2010 Feb; 38(Pt 1):292-6. PubMed ID: 20074077
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of protein geranylgeranyltransferase-I lead to prelamin A accumulation in cells by inhibiting ZMPSTE24.
Chang SY; Hudon-Miller SE; Yang SH; Jung HJ; Lee JM; Farber E; Subramanian T; Andres DA; Spielmann HP; Hrycyna CA; Young SG; Fong LG
J Lipid Res; 2012 Jun; 53(6):1176-82. PubMed ID: 22448028
[TBL] [Abstract][Full Text] [Related]
6. LMNA mutations resulting in lipodystrophy and HIV protease inhibitors trigger vascular smooth muscle cell senescence and calcification: Role of ZMPSTE24 downregulation.
Afonso P; Auclair M; Boccara F; Vantyghem MC; Katlama C; Capeau J; Vigouroux C; Caron-Debarle M
Atherosclerosis; 2016 Feb; 245():200-11. PubMed ID: 26724531
[TBL] [Abstract][Full Text] [Related]
7. HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study.
Perrin S; Cremer J; Faucher O; Reynes J; Dellamonica P; Micallef J; Solas C; Lacarelle B; Stretti C; Kaspi E; Robaglia-Schlupp A; Nicolino-Brunet C; Tamalet C; Lévy N; Poizot-Martin I; Cau P; Roll P
PLoS One; 2012; 7(12):e53035. PubMed ID: 23285253
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial.
Madruga JV; Berger D; McMurchie M; Suter F; Banhegyi D; Ruxrungtham K; Norris D; Lefebvre E; de Béthune MP; Tomaka F; De Pauw M; Vangeneugden T; Spinosa-Guzman S;
Lancet; 2007 Jul; 370(9581):49-58. PubMed ID: 17617272
[TBL] [Abstract][Full Text] [Related]
9. Type B mandibuloacral dysplasia with congenital myopathy due to homozygous ZMPSTE24 missense mutation.
Ben Yaou R; Navarro C; Quijano-Roy S; Bertrand AT; Massart C; De Sandre-Giovannoli A; Cadiñanos J; Mamchaoui K; Butler-Browne G; Estournet B; Richard P; Barois A; Lévy N; Bonne G
Eur J Hum Genet; 2011 Jun; 19(6):647-54. PubMed ID: 21267004
[TBL] [Abstract][Full Text] [Related]
10. [Darunavir in treatment-naïve patients. The ARTEMIS study].
Estrada V; Fuster M
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():10-3. PubMed ID: 19195454
[TBL] [Abstract][Full Text] [Related]
11. Deficiency in ZMPSTE24 and resulting farnesyl-prelamin A accumulation only modestly affect mouse adipose tissue stores.
Heizer PJ; Yang Y; Tu Y; Kim PH; Chen NY; Hu Y; Yoshinaga Y; de Jong PJ; Vergnes L; Morales JE; Li RL; Jackson N; Reue K; Young SG; Fong LG
J Lipid Res; 2020 Mar; 61(3):413-421. PubMed ID: 31941672
[TBL] [Abstract][Full Text] [Related]
12. Effects of ritonavir-boosted darunavir, atazanavir and lopinavir on adipose functions and insulin sensitivity in murine and human adipocytes.
Capel E; Auclair M; Caron-Debarle M; Capeau J
Antivir Ther; 2012; 17(3):549-56. PubMed ID: 22293506
[TBL] [Abstract][Full Text] [Related]
13. Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice.
Fong LG; Ng JK; Meta M; Coté N; Yang SH; Stewart CL; Sullivan T; Burghardt A; Majumdar S; Reue K; Bergo MO; Young SG
Proc Natl Acad Sci U S A; 2004 Dec; 101(52):18111-6. PubMed ID: 15608054
[TBL] [Abstract][Full Text] [Related]
14. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.
Wang Y; Shilagardi K; Hsu T; Odinammadu KO; Maruyama T; Wu W; Lin CS; Damoci CB; Spear ED; Shin JY; Hsu W; Michaelis S; Worman HJ
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35197292
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of ritonavir-boosted protease inhibitor monotherapy in the clinical setting: same results as in clinical trials? The PIMOCS Study Group.
Curran A; Monteiro P; Domingo P; Villar J; Imaz A; Martínez E; Fernández I; Knobel H; Podzamczer D; Iribarren JA; Peñaranda M; Crespo M;
J Antimicrob Chemother; 2014 May; 69(5):1390-6. PubMed ID: 24415645
[TBL] [Abstract][Full Text] [Related]
16. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
17. Zinc metalloproteinase, ZMPSTE24, is mutated in mandibuloacral dysplasia.
Agarwal AK; Fryns JP; Auchus RJ; Garg A
Hum Mol Genet; 2003 Aug; 12(16):1995-2001. PubMed ID: 12913070
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of adipose tissue from Zmpste24-/- mice, a model of lipodystrophy and premature aging, reveals major changes in mitochondrial function and vimentin processing.
Peinado JR; Quirós PM; Pulido MR; Mariño G; Martínez-Chantar ML; Vázquez-Martínez R; Freije JM; López-Otín C; Malagón MM
Mol Cell Proteomics; 2011 Nov; 10(11):M111.008094. PubMed ID: 21828285
[TBL] [Abstract][Full Text] [Related]
19. [Safety and tolerability of darunavir].
Antela López A
Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 10():32-6. PubMed ID: 19195457
[TBL] [Abstract][Full Text] [Related]
20. Lopinavir/ritonavir: appraisal of its use in HIV therapy.
von Hentig N
Drugs Today (Barc); 2007 Apr; 43(4):221-47. PubMed ID: 17460785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
